Table 2. Frequency of LOC387715/ARMS2 (rs10490924) alleles and genotypes in NVAMD patients and unaffected controls.
| LOC387715/ARMS2 (rs10490924) | AMD | Unaffected | p | OR (95% CI) |
|---|---|---|---|---|
| By allele | ||||
| Entire population
(G/T; %)* |
279/219
(56/44) |
190/48
(80/20) |
<0.0001 |
3.1 (2.2–4.5) |
| Ashkenazi Jews |
189/129 (59.4/40.6) |
110/26
(80.8/19.2) |
<0.0001 |
2.9 (1.8–4.7) |
| Sephardic Jews |
76/72
(51.4/48.6) |
63/17
(78.8/21.2) |
<0.0001 |
3.5 (1.9–6.6) |
| Arabs |
8/12
(40/60) |
16/4
(80/20) |
0.022 |
6 (1.5–24.7) |
| By genotype | ||||
| Entire Population |
|
|
<0.0001 |
|
| GG (%) |
91 (36.5) |
77 (64.2) |
|
|
| TG (%) |
97 (39) |
36 (30.3) |
0.0012 |
2.3 (1.4–3.7) |
| TT (%) |
61 (24) |
6 (5) |
<0.0001 |
8.6 (3.5–20.8) |
| Ashkenazi Jews |
|
|
<0.0001 |
|
| GG (%) |
67 (42.1) |
45 (66.2) |
|
|
| TG (%) |
55 (34.6) |
20 (29.4) |
0.17 |
1.6 (3.1–0.82) |
| TT (%) |
37 (23.3) |
3 (4.4) |
0.003 |
9.7 (41.6–2.2) |
| Sephardic Jews |
|
|
0.0003 |
|
| GG (%) |
20 (27) |
26 (65) |
|
|
| TG (%) |
36 (48.6) |
11 (27.5) |
0.003 |
4.3 (10.4–1.7) |
| TT (%) |
18 (24.3) |
3 (7.5) |
0.001 |
7.8 (30.3–2) |
| Arabs# |
|
|
0.036 |
|
| GG (%) |
3 (30) |
6 (60) |
|
|
| TG (%) |
2 (20) |
4 (40) |
|
|
| TT (%) | 5 (50) | 0 (0) | ||
Comparison of the frequency (%) of the LOC387715/ARMS2 (rs10490924) variant between NVAMD patients and controls in the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the T variant was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence interval, OR- odds ratio. The asterisk indicates reliable genotyping for rs10490924 was obtained from 249 of the 255 patients and for each of the 119 controls. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of genotypes in this sub population.